Your session is about to expire
← Back to Search
Pacritinib for Castleman Disease and Syndrome
Study Summary
This trial tests pacritinib to treat KSHV-associated KICS or MCD in people living with HIV.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 1 & 2 trial • 40 Patients • NCT02891603Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
For whom is this clinical trial available?
"This medical trial is seeking approximately 65 individuals with kaposi's sarcoma-associated herpesvirus inflammatory cytokine syndrome who are aged between 18 and 120."
Does the research study accommodate minors?
"Individuals aged 18 to 120 are eligible for this clinical trial, with 531 studies available specifically for minors and 1,414 trials focusing on those older than 65."
What safety measures have been taken to ensure Arm 1 is secure for participants?
"Our internal evaluation of Arm 1's safety ranks it a 2, as there is existing data to suggest that the intervention is safe but no evidence yet regarding effectiveness."
Are participants currently able to enroll in this experiment?
"Clinicaltrials.gov states that this particular study is no longer recruiting, as the last update was made on September 22nd 2023. Despite this, there are a wealth of other trials currently enrolling patients - 1,942 to be exact!"
Share this study with friends
Copy Link
Messenger